C. Berthon

发表

Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies

E. Clappier, A. Stamatoullas, J. Vial, 2018, British journal of haematology.

Clinically Relevant Oxygraphic Assay to Assess Mitochondrial Energy Metabolism in Acute Myeloid Leukemia Patients

B. Quesnel, C. Berthon, J. Kluza, 2021, Cancers.

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Claude Preudhomme, Robert Barouki, Serge Koscielny, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest

Vahid Asnafi, Elizabeth Macintyre, H. Dombret, 2013, Haematologica.

Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults

P. Chevallier, M. Béné, X. Thomas, 2020, Leukemia & lymphoma.

Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities

B. Esterni, G. Mufti, P. Fenaux, 2015, American journal of hematology.

Azacitidine improves outcome in higher‐risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

J. Hernández-Rivas, A. Stamatoullas, P. Fenaux, 2018, British journal of haematology.

Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients

P. Fenaux, C. Berthon, C. Rose, 2013, British journal of haematology.

Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19

B. Quesnel, S. Susen, C. Preudhomme, 2020, Cancers.

Impact of Initial FDG-PET/CT and Serum-Free Light Chain on Transformation of Conventionally Defined Solitary Plasmacytoma to Multiple Myeloma

D. Huglo, O. Decaux, M. Macro, 2014, Clinical Cancer Research.

Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study

H. Dombret, A. Plesa, C. Preudhomme, 2019, Cancers.

Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70‐year old: A phase 1/2 study of the acute leukemia French association

H. Dombret, S. Chevret, C. Gardin, 2012, American journal of hematology.

Is Less Chemotherapy Detrimental in Adults with Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with High-Dose Imatinib? Results of the Prospective Randomized Graaph-2005 Study

J. Cayuela, H. Dombret, S. Leprêtre, 2012 .

Allogeneic stem-cell transplantation with fludarabine and 2-Gy TBI-based conditioning regimen for chronic hematological malignancy: A study of 25 consecutive patients and a literature review

I. Yakoub-Agha, F. Bauters, S. Tricot, 2007, Leukemia & lymphoma.

Familial myeloid malignancies with germline TET2 mutation

G. Huet, B. Quesnel, C. Preudhomme, 2019, Leukemia.

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

A. Stamatoullas, S. Chevret, B. Quesnel, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antifungal stewardship: implementation in a French teaching hospital.

C. Berthon, V. Coiteux, S. Alfandari, 2014, Medecine et maladies infectieuses.

Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype

H. Dombret, C. Preudhomme, X. Thomas, 2019, Cancers.

Therapeutic drug monitoring of aminoglycosides in acute myeloid leukaemia patients

F. Pasquier, C. Berthon, N. Blondiaux, 2012, Scandinavian journal of infectious diseases.

Discontinuation of antimicrobial therapy in adult neutropenic haematology patients: A prospective cohort.

B. Quesnel, M. Titécat, C. Berthon, 2019, International journal of antimicrobial agents.

Pneumatic transport is critical for leukaemic patients with major leukocytosis: what precautions to measure lactate dehydrogenase, potassium and aspartate aminotransferase?

P. Maboudou, C. Berthon, D. Launay, 2010, Annals of clinical biochemistry.

Linezolid induces ring sideroblasts

B. Quesnel, C. Preudhomme, J. Rossignol, 2013, Haematologica.

Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML

E. Clappier, C. Preudhomme, L. Adès, 2022, Blood Cancer Journal.

Abnormal Cytogenetics and Significant Bone Marrow Plasmacytosis are Predictive of Early Progression and Short Survival in Patients with Low Tumor Mass Asymptomatic Multiple Myeloma

B. Quesnel, F. Bauters, X. Leleu, 2004, Leukemia & lymphoma.

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.

C. Preudhomme, C. Gardin, P. Rousselot, 2012, Leukemia research.

Subclonal acquisition of a BCR::ABL1 fusion in a chronic myelomonocytic leukemia

C. Berthon, O. Nibourel, Laure Goursaud, 2022, Annals of Hematology.

Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.

H. Dombret, B. Quesnel, C. Preudhomme, 2015, Leukemia research.

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size

B. Quesnel, A. Marceau, C. Berthon, 2020, Leukemia research reports.

Azacitidine for the treatment of relapsed and refractory AML in older patients.

H. Dombret, A. Stamatoullas, P. Fenaux, 2015, Leukemia research.

Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.

B. Quesnel, P. Fenaux, S. Thépot, 2015, Leukemia research.

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

P. Fenaux, S. Thépot, L. Adès, 2012, Leukemia research.

CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells

B. Quesnel, C. Preudhomme, C. Berthon, 2019, Cancer medicine.

Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine

B. Quesnel, A. Duhamel, C. Preudhomme, 2016, Leukemia.

Hereditary Predisposition to Acute Myeloid Leukemia in Older Adults

C. Preudhomme, C. Berthon, Emma Lachaier, 2021, HemaSphere.

Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification.

B. Quesnel, M. Fontenay, M. Lhermitte, 2013, Leukemia research.

APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)

A. Stamatoullas, S. Chevret, B. Quesnel, 2019, Blood.

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.

H. Dombret, C. Preudhomme, T. Cluzeau, 2021, Blood.

Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA)

H. Dombret, S. Chevret, C. Preudhomme, 2011 .

B7‐H3 protein expression in acute myeloid leukemia

B. Quesnel, C. Preudhomme, C. Berthon, 2015, Cancer medicine.

RIP3 is downregulated in human myeloid leukemia cells and modulates apoptosis and caspase-mediated p65/RelA cleavage

B. Quesnel, E. Bertrand, T. Idziorek, 2014, Cell Death and Disease.

Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis.

B. Quesnel, C. Preudhomme, E. Cornet, 2012, Leukemia research.

GILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells

B. Quesnel, C. Preudhomme, T. Idziorek, 2011, Oncogene.

Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use

H. Dombret, C. Preudhomme, S. de Botton, 2020, Haematologica.

Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies

A. Palumbo, H. Dombret, B. Quesnel, 2014 .

Involvement of ORAI1/SOCE in Human AML Cell Lines and Primary Cells According to ABCB1 Activity, LSC Compartment and Potential Resistance to Ara-C Exposure

M. C. Tarhan, B. Quesnel, T. Idziorek, 2022, International journal of molecular sciences.

Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study.

A. Duhamel, K. Faure, C. Berthon, 2013, American journal of infection control.

A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.

B. Quesnel, X. Leleu, C. Berthon, 2010, Experimental hematology.

Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML)

E. Solary, W. Vainchenker, O. Bernard, 2012 .

Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations

S. Broutin, J. Delahousse, A. Paci, 2018, Leukemia.

Final Analysis of the ALFA 0701 Study

H. Dombret, S. Chevret, C. Preudhomme, 2014 .

Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia

O. Abdel-Wahab, R. Favier, H. Raslova, 2016, Leukemia.

Enteral feeding and early outcomes of patients undergoing allogeneic stem cell transplantation following myeloablative conditioning.

I. Yakoub-Agha, F. Bauters, C. Berthon, 2006, Transplantation.

Long-term follow up of invasive aspergillosis in allogeneic stem cell transplantation recipients and leukemia patients: Differences in risk factors and outcomes.

B. Quesnel, I. Yakoub-Agha, C. Berthon, 2017, Current research in translational medicine.

Germline PAX5 mutation predisposes to familial B acute lymphoblastic leukemia.

C. Preudhomme, Aurélie Caillault, C. Berthon, 2020, Blood.

Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia.

S. Tricot, C. Berthon, S. Alfandari, 2011, Medecine et maladies infectieuses.

A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia.

J. Bourhis, H. Dombret, S. Chevret, 2020, Blood.

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.

J. Bourhis, H. Dombret, C. Preudhomme, 2020, Blood advances.

Clofarabine-Based Consolidation Improves Relapse-Free Survival of Younger Adults with Non-Favorable Acute Myeloid Leukemia (AML) in First Remission: Results of the Randomized ALFA-0702/Clara Study (NCT 00932412)

H. Dombret, S. Chevret, C. Preudhomme, 2015 .

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial

H. Dombret, S. Leprêtre, P. Chevallier, 2015, Haematologica.

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.

J. Cayuela, H. Dombret, S. Chevret, 2013, Blood.

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

J. Cayuela, H. Dombret, C. Preudhomme, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of CD34 in hematopoietic cancer cell lines reflects tightly regulated stem/progenitor‐like state

B. Quesnel, C. Berthon, F. Leprêtre, 2011, Journal of cellular biochemistry.

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association

H. Dombret, C. Preudhomme, P. Fenaux, 2011, Leukemia.

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.

H. Dombret, J. Tamburini, T. Cluzeau, 2014, Blood.

Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia

X Thomas, H. Dombret, C. Preudhomme, 2011, Leukemia.

Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study

W. Hiddemann, R. Schlenk, K. Götze, 2021, Haematologica.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

H. Dombret, B. Quesnel, P. Hérait, 2016, The Lancet. Haematology.

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study.

H. Dombret, C. Preudhomme, L. Adès, 2021, Blood.

Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma.

B. Quesnel, M. Lhermitte, C. Berthon, 2009, Leukemia research.

Repression of the RHOH gene by JunD.

B. Quesnel, C. Shelley, C. Berthon, 2011, The Biochemical journal.

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.

J. Cayuela, H. Dombret, S. Leprêtre, 2015, Blood.

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

H. Dombret, B. Quesnel, C. Preudhomme, 2015, Oncotarget.

Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR–JAK2 fusion transcript

C. Preudhomme, C. Berthon, O. Nibourel, 2016, European journal of haematology.

Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens

A. Duhamel, F. Bauters, X. Leleu, 2006, Annals of Hematology.

Irregular nuclear shape of bone marrow plasma cells defines a multiple myeloma subgroup related to hypodiploidy and to short survival.

A. Duhamel, X. Leleu, J. Andrieux, 2005, Leukemia research.

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

D. Birnbaum, T. Haferlach, E. Solary, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognosis of hypercalcemia in aerodigestive tract cancers: study of 136 recent cases.

C. Fournier, S. Villet, C. Berthon, 2005, Oral oncology.

Baseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignancies

S. Susen, C. Preudhomme, C. Berthon, 2020, British journal of haematology.

Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML.

O. Kepp, G. Kroemer, E. Solary, 2021, Blood.

Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study

Arnaud Pigneux, Elizabeth Macintyre, H. Dombret, 2012, British journal of haematology.

Clonal architecture of chronic myelomonocytic leukemias.

E. Solary, W. Vainchenker, O. Bernard, 2013, Blood.

Thalidomide in multiple myeloma in the elderly

T. Hideshima, A. Roccaro, I. Ghobrial, 2009 .

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia

H. Dombret, B. Quesnel, P. Hérait, 2014 .

Genetic Identification of AML Patients Older than 60 years Achieving Long-term Survival with Intensive Chemotherapy.

H. Dombret, C. Preudhomme, T. Cluzeau, 2021, Blood.

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

F. Pasquier, E. Clappier, J. Cayuela, 2021, Blood.

In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors

B. Quesnel, X. Leleu, C. Berthon, 2010, Cancer Immunology, Immunotherapy.

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

A. Stamatoullas, B. Quesnel, Q. Mo, 2021, Blood.

Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively

E. Clappier, H. Dombret, A. Plesa, 2022, HemaSphere.

Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.

B. Quesnel, C. Berthon, O. Nibourel, 2022, Leukemia research.

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.

H. Dombret, S. Chevret, C. Preudhomme, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

H. Dombret, C. Preudhomme, L. Adès, 2019, Blood.

Gemtuzumab Ozogamicin-Based Salvage, Followed by Allogeneic Hematopoietic Stem Cell Transplantation, Is Highly Effective in Young Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Relapse

H. Dombret, J. Tamburini, T. Cluzeau, 2011 .

Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study

H. Dombret, C. Preudhomme, C. Gardin, 2021, Blood.

Successful bridging to cell therapy for relapsed/refractory acute lymphoblastic leukaemia with a combination of venetoclax and PEG‐asparaginase

B. Quesnel, C. Berthon, Laure Goursaud, 2022, British journal of haematology.

Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.

H. Dombret, S. Leprêtre, R. Gressin, 2021, Clinical lymphoma, myeloma & leukemia.

Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia

B. Quesnel, C. Preudhomme, C. Berthon, 2020, Leukemia.

Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia

B. Quesnel, A. Duhamel, C. Preudhomme, 2016, Oncotarget.

Can palliative care consultation increase integration of palliative care for patients with hematologic malignancies?

L. Touzet, T. Facon, C. Berthon, 2021, Blood advances.

UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia

J. Soulier, E. Clappier, H. Dombret, 2023, Leukemia.

LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study

H. Dombret, C. Preudhomme, S. de Botton, 2023, Blood advances.

H. Dombret, P. Fenaux, S. Thépot, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Carbapenems and febrile neutropenia.

C. Berthon, S. Alfandari, F. Ader, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Clinico‐biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi‐centric observational study

J. Tamburini, D. Bouscary, C. Berthon, 2023, British journal of haematology.

Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial

J. Cayuela, H. Dombret, M. Béné, 2011 .

Targeting Aberrant Expression of CD81 Impacts Cell Adhesion and Migration, Drug Resistance and Prognosis of Acute Myeloid Leukemia

C. Preudhomme, C. Berthon, C. Roumier, 2017 .

Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA)

B. Quesnel, C. Preudhomme, P. Fenaux, 2014 .

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.

H. Dombret, J. Tamburini, T. Cluzeau, 2014, Blood.

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

H. Dombret, E. Solary, O. Bernard, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.